A detailed history of Captrust Financial Advisors transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Captrust Financial Advisors holds 468,106 shares of BMY stock, worth $27.1 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
468,106
Previous 412,972 13.35%
Holding current value
$27.1 Million
Previous $17.2 Million 41.25%
% of portfolio
0.07%
Previous 0.06%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $2.19 Million - $2.85 Million
55,134 Added 13.35%
468,106 $24.2 Million
Q2 2024

Aug 14, 2024

SELL
$40.25 - $52.99 $1.44 Million - $1.89 Million
-35,757 Reduced 7.97%
412,972 $17.2 Million
Q1 2024

May 15, 2024

SELL
$47.98 - $54.4 $3 Million - $3.4 Million
-62,577 Reduced 12.24%
448,729 $24.3 Million
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $2.74 Million - $3.27 Million
-56,523 Reduced 9.95%
511,306 $26.2 Million
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $482,628 - $539,654
8,337 Added 1.49%
567,829 $33 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $1.11 Million - $1.23 Million
17,369 Added 3.2%
559,492 $35.8 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $1.78 Million - $2.01 Million
27,024 Added 5.25%
542,123 $37.6 Million
Q4 2022

Feb 15, 2023

BUY
$68.48 - $81.09 $1.16 Million - $1.37 Million
16,888 Added 3.39%
515,099 $37.1 Million
Q3 2022

Nov 16, 2022

BUY
$0.13 - $76.84 $15,159 - $8.96 Million
116,613 Added 30.56%
498,211 $35.4 Million
Q2 2022

Aug 23, 2022

SELL
$72.62 - $79.98 $2.24 Million - $2.47 Million
-30,910 Reduced 7.49%
381,598 $29.6 Million
Q2 2022

Aug 16, 2022

BUY
$72.62 - $79.98 $5.7 Million - $6.28 Million
78,552 Added 23.52%
412,508 $31.8 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $1.78 Million - $2.13 Million
28,924 Added 9.48%
333,956 $24.6 Million
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $1.38 Million - $1.6 Million
25,663 Added 9.19%
305,032 $19 Million
Q3 2021

Nov 16, 2021

BUY
$59.17 - $69.31 $2.54 Million - $2.97 Million
42,855 Added 18.12%
279,369 $16.7 Million
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $306,392 - $333,661
-4,949 Reduced 2.05%
236,514 $15.8 Million
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $392,593 - $441,551
6,616 Added 2.82%
241,463 $15.4 Million
Q4 2020

Feb 16, 2021

BUY
$57.74 - $65.43 $115,595 - $130,990
2,002 Added 0.86%
234,847 $14.7 Million
Q3 2020

Nov 17, 2020

BUY
$57.43 - $63.64 $380,760 - $421,933
6,630 Added 2.93%
232,845 $14 Million
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $1.15 Million - $1.35 Million
21,052 Added 10.26%
226,215 $13.4 Million
Q1 2020

May 15, 2020

BUY
$46.4 - $67.43 $584,129 - $848,876
12,589 Added 6.54%
205,163 $11.2 Million
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $5.39 Million - $7.03 Million
109,531 Added 131.9%
192,574 $12.2 Million
Q3 2019

Nov 14, 2019

BUY
$42.77 - $50.71 $40,503 - $48,022
947 Added 1.15%
83,043 $4.21 Million
Q2 2019

Aug 13, 2019

BUY
$44.62 - $49.34 $266,604 - $294,806
5,975 Added 7.85%
82,096 $3.72 Million
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $130,035 - $155,051
2,882 Added 3.94%
76,121 $3.63 Million
Q4 2018

Feb 13, 2019

SELL
$48.76 - $63.23 $138,429 - $179,509
-2,839 Reduced 3.73%
73,239 $3.81 Million
Q3 2018

Nov 15, 2018

BUY
$55.19 - $62.25 $1.84 Million - $2.08 Million
33,340 Added 78.01%
76,078 $4.72 Million
Q2 2018

Aug 13, 2018

BUY
$50.53 - $62.98 $544,612 - $678,798
10,778 Added 33.72%
42,738 $2.37 Million
Q1 2018

May 15, 2018

SELL
$59.92 - $68.98 $592,788 - $682,419
-9,893 Reduced 23.64%
31,960 $1.98 Million
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $2.36 Million - $2.58 Million
39,423 Added 1622.35%
41,853 $2.57 Million
Q3 2017

Feb 16, 2018

BUY
$55.23 - $63.74 $134,208 - $154,888
2,430
2,430 $155,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.